BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CTMSS - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CTMSS
X-ORIGINAL-URL:https://clinicaltmssociety.org
X-WR-CALDESC:Events for CTMSS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20200101T000000
END:STANDARD
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200803
DTEND;VALUE=DATE:20241108
DTSTAMP:20260608T114752
CREATED:20241107T194636Z
LAST-MODIFIED:20241108T134638Z
UID:1493-1596412800-1731023999@clinicaltmssociety.org
SUMMARY:TOP 6 Flash Poster Presentations Webinar
DESCRIPTION:TOP 6 Flash Poster Presentations Webinar \nTuesday\, August 4\, 2020\n8 pm EDT\, 7 pm CDT and 5 pm PDT\nSince 2018\, CTMSS has provided a speaking platform for the Top 4 Poster Abstracts at the Annual Meeting. We are thrilled to be able to continue to share our top research and findings. \nThe Abstract Review Committee decided to include an additional two abstracts this year to be presented since the 2020 Annual Meeting in Chicago was regrettably canceled. These abstracts were originally scheduled as general presentations for the conference and as such\, were not eligible for being selected to present during this session. Thus\, this year there will be a total of 6 top abstracts presented. \nThe following Top 6 Poster Presentations Webinar is scheduled for Tuesday\, August 4\, 2020\, and will be moderated by our Abstract Review Committee\, F. Andrew Kozel\, M.D.\, M.S.C.R. \n\nAbstract #6: Anhedonia in Major Depressive Disorder: Can it be the Chicken and the Egg for Transcranial Magnetic Stimulation?\nAbstract #17: Does it Matter if Depressed Patients get TMS Sessions Less Often than 5 Times per Week? A Treatment Schedule Density Analysis\nAbstract #25: Systematic Review and Meta-Analysis Comparing iTBS vs. TMS vs. Sham in Randomized Controlled Trials\nAbstract #41: Evaluation of Cognitive Performance in Clinically Depressed Patients Using THINC-it® After rTMS Treatment\nAbstract #45: A Multicenter\, Randomized\, Sham-Controlled Trial of Left Prefrontal\, 10 Hz\, Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression\nAbstract #64: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT-TRD) Induces Rapid remission from Treatment-Resistant Depression in a Double-Blinded\, Randomized\, and Controlled Trial\n\nCME will not be provided for this webinar. \nFREE TO REGISTER! \nFormat: Webinar using Zoom Video Communications \n*The Webinar log-in information will be sent out via email the day prior and the morning of the webinar. \nOnline registration ENDS Monday\, August 3\, 2020\, at 3 pm PDT
URL:https://clinicaltmssociety.org/event/top-6-flash-poster-presentations-webinar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Top_6_Abstract_Webinar_Recordings.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200929
DTEND;VALUE=DATE:20241108
DTSTAMP:20260608T114752
CREATED:20241107T195053Z
LAST-MODIFIED:20241108T134600Z
UID:1498-1601337600-1731023999@clinicaltmssociety.org
SUMMARY:CTMSS Product Theater Webinar with NEUROSTAR
DESCRIPTION:CTMSS Product Theater Webinar\n \nDate: Tuesday\, September 29\, 2020\nTime: 5:00 pm PDT / 7:00 pm CDT / 8:00 pm EDT \nTreating Depression Episodes – New Research Data before Publication\nEfficacy of NeuroStar TMS in Bipolar and Unipolar Depression \nTreatment of Bipolar Depression: A Pilot Study presented by Scott Aaronson\, M.D. \nThe majority of time patients with bipolar disorder are ill\, they are depressed.  There are few FDA approved treatments for bipolar depression and all of them are second-generation antipsychotics which carry a high side effect burden.  Clinical experience has suggested that TMS might be effective for bipolar depression.  This presentation will review the existing literature on the efficacy of TMS for bipolar depression and present the findings from a two-center open-label prospective trial of TMS in bipolar depression including type I and type II patients. \nAt the end of the presentation\, attendees will gain an understanding of the existing literature on the efficacy of TMS for bipolar depression and learn additional insights from an examination of a two-center open-label trial. \nClinical Outcomes of NeuroStar TMS treatment: The Largest Patient Registry for Depression Treatment with Transcranial Magnetic Stimulation presented by Harold Sackeim\, Ph.D. \nNeuroStar® Advanced Therapy System Clinical Outcomes Registry has documented treatment parameters and clinical outcomes in over 9\,000 unique individuals treated at over 100 private practice sites in the US. This presentation reports new findings regarding the efficacy of TMS in adult patients treated for an episode of major depressive disorder in community settings.  Demographic and treatment parameter correlates of treatment outcomes will be examined.  New findings will also be presented regarding the relative efficacy of the Standard NeuroStar protocol (inter-train interval of 26 s; 38-minute session) and the Dash protocol (inter-train interval of 11 s; 19-minute session). \nAt the end of the presentation\, attendees will gain insights into the real-world treatment outcomes of MDD and the efficacy of TMS leveraging the largest clinical data set in MDD. \nFormat: LIVE \nFREE TO REGISTER! \nRegister online by Monday\, September 28\, 2020. \n**Webinar log-in information will be sent out via email the day prior on September 28\, 2020. \nDisclaimer: The content does not necessarily reflect the views and opinions of Clinical TMS Society or its members and is solely determined by the sponsor. \n\nPresenters: \n\nScott Aaronson\, M.D. \nDr. Scott Aaronson is director of clinical research programs\, director of transcranial magnetic stimulation services\, and chair of the medical executive committee at Sheppard Pratt Health System in Baltimore\, Maryland. He is an Adjunct Professor in the Department of Psychiatry at the University of Maryland School of Medicine. Dr. Aaronson specializes in treatment-resistant affective disorders. He is a thought leader in the areas of biological psychiatry\, diagnosis\, and the integration of somatic and psychological therapies\, and is the principal investigator for multiple studies on the development of novel therapies for mood and anxiety disorders. Dr. Aaronson is a valued speaker and educator and frequently lectures both regionally and nationally on mood disorders\, including the integration of biological and psychotherapies\, complex mood disorders\, psychoeducation\, and the development of new therapies. Much of his research work and publications center on the development of various neurostimulation paradigms including Transcranial Magnetic Stimulation\, Vagus Nerve Stimulation\, Direct Current Stimulation\, and synchronized TMS to treat severe mood disorders.  Recently\, he has begun research into the use of psychedelics in mood disorders including three studies looking at psilocybin in various presentations of depression.  He is a member of the board of directors of the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr Aaronson earned his MD with honors from Harvard Medical School. He completed a residency in psychiatry at McLean Hospital\, as well as a fellowship in sleep physiology at Harvard Medical School.  He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American College of Psychiatrists. \n\nHarold A. Sackeim\, Ph.D. \nDr. Harold A. Sackeim is Professor of Clinical Psychology in Psychiatry and Radiology\, College of Physicians and Surgeons\, Columbia University.  He served as Chief of the Department of Biological Psychiatry at the New York State Psychiatric Institute for 25 years. He is also the Founding Editor of the journal\, Brain Stimulation: Basic\, Translational\, and Clinical Research in Neuromodulation.  He received his first B.A. from Columbia College\, Columbia University (1972)\, another B.A. and an M.A. from Magdalen College\, Oxford University (1974) and his Ph.D. from the University of Pennsylvania (1977)\, where he also completed his clinical training in the Department of Psychiatry. He joined the faculty of Columbia University in 1977\, where he remains today. \n\n\n\nWhen\nSeptember 29th\, 2020 from  5:00 PM to  6:00 PM
URL:https://clinicaltmssociety.org/event/ctmss-product-theater-webinar-with-neurostar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/NeuroStar_Product_Theater_Event_Thumbnail.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210113
DTEND;VALUE=DATE:20241108
DTSTAMP:20260608T114752
CREATED:20241107T195428Z
LAST-MODIFIED:20241108T134541Z
UID:1502-1610496000-1731023999@clinicaltmssociety.org
SUMMARY:January 13\, 2021 Town Hall Member Meeting
DESCRIPTION:January 13\, 2021 Annual Town Hall Member Meeting  \nYou’re invited to join the Clinical TMS Society for the January 13\, 2021 Annual Town Hall Member Meeting.  \nPresentation Overview:  \nJoin the Clinical TMS Society President\, Kimberly Cress\, MD\, President-Elect\, Randy Pardell\, MD\, and our current committee co-chairs for an update on all 2020-2021 committee projects. \nThis is your opportunity to learn more about the various goals and projects\, ask questions and provide feedback. \nDate: January 13\, 2021 \nFormat: ON-DEMAND \nThis meeting is for current members only.  \n\nSPEAKERS:  \nJohn O'Reardon\, MD\, CTMSS Annual Meeting Committee Co-chair\nDr. O’Reardon has been in practice as a psychiatrist for 30 years. He completed his residency training at Penn and Fellowships in Psychopharmacology & Cognitive Therapy (including training at the Beck Institute). In his clinical work as a faculty member at Penn he focused on treatment-resistant mood disorders and neuromodulation. This is the development of brain devices to stimulate the brain and treat mood disorders. These devices\, which are increasing all the time\, include transcranial magnetic stimulation (TMS)\, deep brain stimulation (DBS)\, vagus nerve stimulation (VNS)\, EEG-synchronized TMS (sTMS)\, deep TMS (dTMS) and transcranial direct current stimulation (tDCS). \nDr. O’Reardon was an active educator at Penn and over the years helped train more than a hundred psychiatry residents. He taught courses on neuromodulation\, mood disorders and the History of Psychiatry. He has been a recipient of numerous teaching awards including the Earl Bond Award for excellence in teaching. He has been a frequent presenter at the annual meeting of the American Psychiatric Association (APA). Most recently he has presented a symposium on historical figures and mood disorders called Art\, Politics and Creativity: Resilience in the Face of Great Odds – including Abraham Lincoln\, Vincent Van Gogh\, Winston Churchill and Sylvia Plath. \nDr. O’Reardon has been an active and productive researcher during his career. He has authored over a hundred publications in his career encompassing new brain devices (TMS\, sTMS\, VNS\, DBS and tDCS)\, major depression\, bipolar disorder\, ECT and the night eating syndrome. He has been a lead investigator in many cutting edge clinical trials of new treatments for patients. He is first author on the primary trial that led to FDA approval for TMS as new exciting treatment for major depression. His current research work is with another exciting emerging treatment modality for major depression\, namely tDCS. \nSuzanne Kerns\, MD\, CTMSS Education Committee Co-chair\nDr. Suzanne Kerns is an Assistant Professor of Psychiatry in the Brain Stimulation Service at the Medical University of South Carolina. She serves as the Co-Chair of the Education Committee\, alongside Dr. Michelle Cochran\, and sits on the Board of Directors of the Clinical TMS Society.  Dr. Kerns is experienced in the use of a variety of neuromodulation techniques including ECT\, TMS\, DBS\, and VNS. Her special interests include expanding the use of brain stimulation within Women's mental health\, neuromodulation education\, and holistic and integrative approaches to brain health. \nMartha Koo\, MD\, CTMSS Research Committee Co-chair\nMartha B Koo\, M.D\, has offered psychiatry and psychoanalysis in her private practice in Manhattan Beach\, CA\, since 1996. In 2009\, she certified in Transcranial Magnetic Stimulation. She is the Founder of Neuro Wellness Spa\, a mental health company with four locations that offers rTMS\, IV ketamine\, iV nutrition and photobiomodulation. Dr. Koo joined the CTMSS Board of Directors in 2020 and is co-chair of the Research Committee. \nMohamed Abdelghani\, MBBCh\, MSc\, MRCPsych\, CTMSS Outreach Committee Co-chair\nDr Mohamed Abdelghani is a consultant psychiatrist in London in the UK. He founded the first clinical TMS service in the NHS (public sector) in London and South England. He is actively involved in TMS clinical research and he is the London Principal Investigator for the BRIGhTMIND TMS Randomised Control Trial. In addition to the TMS service he runs in the NHS Dr Abdelghani also offers TMS through his private clinic. \nPaul Croarkin\, DO\, CTMSS Clinical Standards Committee Co-chair\nDr. Croarkin’s research program focuses on adapting and innovating brain stimulation interventions in children and adolescents.  This includes biomarker work to optimize diagnostic practices and the delivery of brain based interventions such as transcranial magnetic stimulation.  A central theme focuses on the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. Dr. Croarkin is a professor of psychiatry in the Mayo Clinic College of Medicine. \nRebecca Allen\, MD\, CTMSS Insurance Committee Co-chair\nDr. Allen has authored several papers and participated in research on sleep and memory consolidation\, quality of life in multiple sclerosis\, comparing TMS protocols and other projects. She authored a chapter on Sleep and Sleep Disorders for the Harvard textbook Neuropsychiatry and Behavioral Neurology: Principles and Practice (2020).  Her main clinical interest is neuropsychiatry: she is trained in the neurobiological bases and treatment of cognitive and behavioral manifestations of neurodegenerative diseases (dementia)\, multiple sclerosis\, epilepsy\, stroke\, brain tumors\, developmental disorders\, traumatic brain injury and other disorders. Other clinical interests include electroconvulsive therapy\, transcranial magnetic stimulation\, and the interaction between sleep and psychiatric disorders. She has held local and national leadership positions\, including serving on the Board of the Clinical TMS Society and as the President of the Washington State Psychiatric Association for 2020-21. \nKen Goolsby\, MD\, CTMSS Membership Committee Co-chair\nKenneth E. Goolsby\, MD has been in private practice in Gainesville since 1987. As a child\, adolescent and adult psychiatrist\, he provides diagnostic evaluations\, individual and family psychotherapy\, medication evaluation and management\, crisis intervention\, and chemical dependency evaluations. Dr. Goolsby provides inpatient hospital care as well as outpatient care. \nDr. Goolsby earned his bachelor's degree at the University of Georgia and his medical degree at the Medical College of Georgia. He completed his psychiatric residency at the William S. Hall Psychiatric Institute Emory University. He then completed his child psychiatry fellowship at William S. Hall Psychiatric Institute. He is a diplomate of the American Board of Psychiatry and Neurology. \nIan Cook\, MD\, CTMSS Legal\, Business\, and Ethics Commitee Co-chair\nIan A. Cook\, M.D. holds the Joanne and George Miller and Family Endowed Chair in Depression Research. He is a Professor of Psychiatry and Biobehavioral Sciences in the David Geffen School of Medicine\, and a Research Scientist at the Semel Institute for Neuroscience and Human Behavior. Dr. Cook received his bachelors degree with high honors from Princeton University and his medical degree from the Yale University School of Medicine. He completed his psychiatry residency training at UCLA's Neuropsychiatric Institute\, where he also was an NIMH-funded research fellow. Dr. Cook served on the Executive Committee on Practice Guidelines of the American Psychiatric Association\, and guided the electronic dissemination of their evidence-based guidelines in psychiatry. A board-certified Psychiatrist\, he has also served as an examiner for the American Board of Psychiatry and Neurology. His biography is profiled in Who's Who in America\, Who's Who in the World\, and Best Doctors. He is the author of numerous publications on brain function in mental illness and in aging\, and holds several patents on biomedical devices and methods. \nMichelle Cochran\, MD\, CTMSS Education Committee Co-chair\, Practice Guidelines Committee Co-chair\, ACROSS Representative to APA\nDr. Cochran currently works as the medical director of the Nashville Center for Hope & Healing and the NeuroScience and TMS treatment centers; in addition she maintains a role as a private practice psychiatrist.  Dr Cochran has experience treating a variety of psychiatric conditions\, using a comprehensive approach with therapy\, counseling\, pharmacogenomic testing\, medication\, and neuromodulation. She received her undergraduate degree at Centre College\, her medical training at University of Louisville School of Medicine\, and she completed her postgraduate medical education at Vanderbilt University Medical Center in Nashville\, Tennessee. During her psychiatry residency she was Chief Resident.  Additionally\, she completed the Management Program for Physicians and Senior Healthcare Administrators at Vanderbilt University\, Owen School of Management.  A current diplomat of the American Board of Psychiatry and Neurology (with active maintenance of certification)\, Dr. Cochran is a member of the Tennessee Psychiatric Association\, Tennessee Medical Association\, Nashville Academy of Medicine\, Tennessee Women in Medicine\, and Southern Psychiatric Association. Since her residency years\, she has also been a member\, Fellow (2011)\, and now Distinguished Fellow (2018) of the American Psychiatric Association. Dr. Cochran has been on the Clinical Faculty in the Department of Psychiatry at Vanderbilt University Medical Center since 1996 and has lectured to undergraduate\, graduate\, and postgraduate students as well as private practitioners.  For over 15 years\, she has been active on numerous advisory boards professionally and personally.  Before retiring from inpatient psychiatric care and establishing her outpatient private practice\, she was the medical director for many psychiatric units and programs in the Middle Tennessee area. Since 2011\, Dr. Cochran has offered repetitive transcranial magnetic stimulation to her patients as an option for the treatment of Major Depressive Disorder.  Dr. Cochran and her staff have trained extensively in the use of repetitive transcranial Magnetic Stimulation (rTMS) including training at Berenson Allen’s Non-Invasive Brain Institute\, Duke University and other specific advanced device trainings.  She has been active in the Clinical TMS Society (CTMSS) on many levels including serving on the executive committee as the VP-Elect (2016-2017)\, President (2017-2018)\, and with the Education and Annual meeting committees.  Most recently she has been helping advance the PULSES introductory course with other active CTMSS board members. \nMODERATED BY:  \nRandy Pardell\, MD\, CTMSS President Elect\nDr. Pardell is currently the Vice President/President-elect of the Clinical TMS Society.  He has served on the Board of Directors of CTMSS for the past 4 years and has been elected to the Executive Committee as Member at Large for two terms and now as Vice President. He has been past Chairman of the Outreach Committee and has served on the Membership and Education Committees. He has been a returning lecturer for the CTMSS Pulses Course.   He has been practicing TMS therapy since 2009. He co-wrote the first lay book on TMS called 3000 Pulses. Dr. Pardell is an honors graduate of the University of Pennsylvania and New York University School of Medicine. He completed his residency and chief residency at the St. Luke’s Roosevelt Medical Center and Post-Doctoral Fellowship at Columbia University where he performed smoking cessation research with Alexander Glassman MD. After graduation from his psychiatric training\, Dr. Pardell moved up with his wife to the beautiful Hudson Valley\, New York to start a practice and raise a family. Dr. Pardell is a Distinguished Life Fellow of the American Psychiatric Association and has been a past President of the Mid-Hudson Psychiatric Society and had been its Program Director for over a decade. Dr. Pardell founded Riverview Psychiatric Medicine\, PC and TMS Center of the Hudson Valley and leads an active group psychiatric and TMS practice. 
URL:https://clinicaltmssociety.org/event/january-13-2021-town-hall-member-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/2021_Annual_Town_Hall_Member_Meeting_Thumbnail_V5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241107
DTEND;VALUE=DATE:20241108
DTSTAMP:20260608T114752
CREATED:20241107T205012Z
LAST-MODIFIED:20260506T155917Z
UID:1528-1730937600-1731023999@clinicaltmssociety.org
SUMMARY:Residents\, Trainee Doctors\, & Medical Students | CTMSS Education Slide Deck: Transcranial Magnetic Stimulation (TMS) - An Introduction
DESCRIPTION:>>WATCH NOW<<\nLearning objectives: \nPart 1: TMS in Depression \n\nUnderstand the evidence for transcranial magnetic stimulation (TMS) as a treatment for depression\nDescribe where TMS falls in a major depressive disorder (MDD) treatment algorithm\nKnow the history of TMS\nUnderstand potential mechanisms of actions of TMS\nKnow the efficacy rate of TMS for MDD from scientific literature\n\nPart 2: Beyond Depression \n\nKnow FDA cleared psychiatric indications for TMS\nUnderstand the basic neurobiology of OCD and addictions as related to the potential mechanism of TMS\nReview the data supporting the use of TMS for OCD and smoking cessation\nIdentify the potential risks of TMS\nUnderstand patient appropriateness for TMS based on demographics\, diagnosis\, and treatment history\n\nCost: Free\nPlease register to view the presentation. On-demand video will populate at the bottom of this page once registered.  To access the powerpoint presentation slide deck\, you must also complete the Education Slide Deck Member User Agreement. At the bottom of this recording you will be prompted to complete a brief survey.  \n\nSpeakers: Kristin Raj\, MD & Suzanne Kerns\, MD \nDr. Raj specializes in the treatment of mood disorders with expertise in neuromodulation and in the psychopharmacological management of the bipolar disorder. She is Chief of Interventional Psychiatry and Chief of the Bipolar Clinic at Stanford University. She is the director of education for interventional psychiatry where she manages resident and fellow education in brain stimulation and the development of didactics. She is also director of the neuroscience curriculum for the psychiatry residency where she has worked to create and assess a new series of interactive lectures. She trained in biomedical engineering in undergraduate at Case Western Reserve University and completed her medical degree and psychiatry residency at Stanford University. She currently serves on the Board of Directors and the Education Committee of the Clinical TMS Society. \nDr. Kerns completed her undergraduate studies at the University of North Carolina in Chapel Hill. She attended medical school at the University of Sydney in Australia\, followed by a psychiatry residency at Duke University Medical Center. Dr. Kerns subsequently completed a year-long Fellowship in Brain Stimulation at the Medical University of South Carolina (MUSC) under the guidance of Dr. Mark George\, a founding father of TMS. After several years of private practice at Seattle Neuropsychiatric Treatment Center with a faculty appointment at the University of Washington\, she returned to MUSC\, where she is now an Assistant Professor of Psychiatry on the Brain Stimulation Service.  Dr. Kerns is a past member of the Board of Directors of the Clinical TMS Society\, past Member-at-Large on the CTMSS Executive Committee\, past Co-Chair of the CTMSS Education Committee\, and she continues to proudly serve as a member of the Education Committee and Resident Education Task Force for the Clinical TMS Society. \n\n\nIf you have any questions\, please email: info@clinicaltmssociety.org
URL:https://clinicaltmssociety.org/event/residents-trainee-doctors-medical-students-ctmss-education-slide-deck-transcranial-magnetic-stimulation-tms-an-introduction/
CATEGORIES:On-Demand Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20241107T080000
DTEND;TZID=UTC:20241107T170000
DTSTAMP:20260608T114752
CREATED:20241107T205252Z
LAST-MODIFIED:20260506T155952Z
UID:1539-1730966400-1730998800@clinicaltmssociety.org
SUMMARY:CTMSS On-Demand Webinar: An Introduction to TMS
DESCRIPTION:>>WATCH NOW<<\n*NEWLY UPDATED* CTMSS On-Demand Webinar: An Introduction to TMS\nRelease Date: January 1\, 2023 \nExpiration Date: December 31\, 2024 \nThe Clinical TMS Society is offering a 4 part on-demand webinar focused on the introduction to TMS. \nCTMSS On-Demand Webinar: An Introduction to TMS is geared primarily for new clinicians and TMS operators/technicians. In addition\, experienced clinicians and technicians who seek a stronger knowledge base would also benefit from the review and updates. \nParticipants will learn: \n\nthe history of rTMS\, including a knowledge of indications\, clinical efficacy\, review of data;\na review of the significant scientific literature giving rise to the technology's adoption;\nan understanding of practical office implementation;\na review of the evidence for conditions other than depression\n\nFormat: On-Demand Webinar \nCost: \n\nCTMSS Members | $150 USD\nNon-members | $300 USD\n\nYou will receive immediate access to the video. \n\n\n\nPresenters: \n\nDebra Stultz\, MD\, FCTMSS \nDr. Debra J. Stultz is the Director and Owner of Stultz Sleep and Behavioral Health in Barboursville\, West Virginia. Dr. Stultz earned her medical degree from Marshall University School of Medicine in Huntington\, West Virginia. She completed a residency in psychiatry and a fellowship in child/adolescent psychiatry through West Virginia University at their Charleston Division through Charleston Area Medical Center in Charleston\, West Virginia. She is board certified in psychiatry\, sleep medicine\, and behavioral sleep medicine.  With a special interest in Narcolepsy\, she treats a variety of sleep disorders and psychiatric issues.  Her specialty in psychiatry is treatment-resistant depression. She is also the editor for the Clinical TMS Society Newsletter\, on their Board of Directors\, Co-Chair of the Education Committee\, and the chairman of the TMS and Sleep Disorders Affinity Group. \n\nJonathan Becker\, DO \nDr. Becker completed his undergraduate and Masters degrees in Developmental Psychology at Tulane University in New Orleans before attending Des Moines University for medical school. He completed his psychiatry residency program at Vanderbilt University and served as a faculty member there for 7 years. While at Vanderbilt\, Dr. Becker served as the medical director of the neuromodulation service from 2017 – 2022. He joined the Neuroscience and TMS Treatment Center in Brentwood\, TN in January 2021. He is an active member of the Clinical TMS Society and a member of the Education Committee. \n\nNicholas Mischel\, MD\, PhD\nDr. Mischel is an Assistant Professor and Director of Interventional Psychiatry and Neuromodulation Research at Wayne University School of Medicine\, in their Department of Psychiatry and Behavioral Neurosciences. He completed his psychiatry residency at Duke University Medical Center\, focusing on brain stimulation clinical/translational research. He now focuses on medication-resistant mood disorders using rTMS and rapid-acting antidepressant medication infusions. He is a member of the Clinical TMS society and is on the Outreach and Education Committees. \nSandeep Vaishnavi\, MD\, PhD \nDr. Vaishnavi received his medical degree from the University of Alabama at Birmingham and completed his residency at Duke University. He completed a visiting fellowship in Transcranial Magnetic Stimulation at Duke University. He is an Adjunct Associate with the Department of Medicine-Pulmonary at Duke University\, is a faculty member with the Duke Visiting Fellowship program in Transcranial Magnetic Stimulation\, is a member of the faculty network for the Duke Institute for Brain Sciences\, is Director of Mindpath Care Centers Clinical Trails Institute\, and a member of the Corporate Governance Board for MindPath Care Centers. He is a member of Clinical TMS Society and is on the Education Committee. \n 
URL:https://clinicaltmssociety.org/event/ctmss-on-demand-webinar-an-introduction-to-tms-2/
CATEGORIES:On-Demand Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241112T120000
DTEND;TZID=America/New_York:20241112T130000
DTSTAMP:20260608T114752
CREATED:20241017T005549Z
LAST-MODIFIED:20260506T155845Z
UID:1172-1731412800-1731416400@clinicaltmssociety.org
SUMMARY:Non-Invasive Brain Stimulation to Treat Chronic Pain Targets\, Mechanisms and Clinical Outcomes
DESCRIPTION:> >Watch Now <<\nYou are invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series\, Non-Invasive Brain Stimulation to Treat Chronic Pain Targets\, Mechanisms and Clinical Outcomes\, presented by Daniel Ciampi de Andrade\, MD\, PhD. \nDr. Daniel Ciampi de Andrade is a clinical neurologist currently focused on teaching and doing research on chronic pain. He has a strong interest on the use of rTMS for the management of neurological diseases\, chronic pain in particular. As rTMS enter guidelines for the managements of chronic pain\, Dr. Daniel Ciampi de Andrade will provide an update on the mechanisms of action of rTMS for pain management\, and how it can be used to aid people with chronic pain in their quest for adequate pain relief.\nAt the end of this presentation\, attendees will: \n\nHave a clear understanding on how chronic pain syndromes are classified.\nHave a general knowledge of the treatment options for the most common pain syndromes.\nUnderstand how neuromodulation\, in particular rTMS\, can be added to the treatment plan as backed up by evidence.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \nOne hour CME credit is available - Click here for CE Language \nDate/Time: \nUSA - November 12\, 2024 at 12:00pm EST | 9:00am PST\nUK- November 12\, 2024 at 5:00pm GMT\nAustralia- November 13\, 2024 at 4:00am AEDT \nFormat: Live Webinar \nCost: Members: $25 | Non-members $50 | Trainee Members FREE \nCan't make this time and date? All Grand Rounds are recorded and available On-Demand to all registered attendees. Recordings are available Friday after the live event. \n\nSpeaker: Daniel Ciampi de Andrade\, MD\, PhD \n \nDr. Daniel Ciampi de Andrade is an associate professor and researcher at the Center of Neuroplasticity and Pain\, Department of Health Science and technology and Faculty of Medicine\, Aalborg University\, Denmark. \nDr. Daniel Ciampi de Andrade trained as a clinical neurologist at the University of Sao Paulo\, Brazil\, and in France (Université Paris-Saclay /Université Paris XII). He trained with Didier Bouhassira\, Nadine Attal and Jean-Pascal Lefaucheur during his stay in Paris\, France\, coming back to Sao Paulo\, Brazil in 2009. He then was appointed coordinator of the Multidisciplinary Pain Center of the Neurology Department\, at the University of Sao Paulo. This center was founded by his mentor\, Professor Manoel Jacobsen Teixeira\, in 1974 and is one of the largest pain centers in Latin America. Dr. Daniel Ciampi de Andrade co-founded and was vice chair of the Medical Research Laboratory of “invasive neuroscience” from 2019 to 2021. \nIn 2021 he moved to Aalborg and joined CNAP. His research has been focused on pain in neurological diseases and neuromodulation for pain relief. In particular\, he has performed research on how pain can influence cortical connectivity and how this information can be used to inform personalized treatment approaches. \nDr. Daniel Ciampi de Andrade has been serving as Vice-Chair of EFIC´s Research Committee since 2024\, section editor of the European Journal of Pain since 2016\, and advisory Board of Pain Reports since 2018. He as published more than 180 peer-reviewed studies\, along with pain book editing and several international book chapters. He received a European Research Council grant that will allow him to continue research\, paired with an amazing team of colleagues at CNAP\, to further explore the effects of pain in the human brain. \n> >Watch Now <<\n\n  \n\n\n\nWhen\nNovember 12th\, 2024 from  9:00 AM to 10:00 AM\n\n\n\nLocation\n\nUnited States\n\n\n\n\nContact\n\nPhone: info@clinicaltmssociety.org\nEmail: info@clinicaltmssociety.org\n\n\n\n\nEvent Fee(s)\n\n\n\n\nFee Level\n\n\n\nWebinar Registration | Member\n$25.00\n\n\nWebinar Registration | Non-Member\n$50.00\n\n\nWebinar Registration | Student\n$0.00\n\n\nWebinar Registration | Associate Member\n$25.00\n\n\nSpeaker Price\n-$50.00
URL:https://clinicaltmssociety.org/event/non-invasive-brain-stimulation-to-treat-chronic-pain-targets-mechanisms-and-clinical-outcomes/
CATEGORIES:All Events,Grand Rounds Webinar
END:VEVENT
END:VCALENDAR